EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Frontline Therapy in Diffuse Large B‐Cell Lymphoma: Evolving Standards, Biological Insights, and Future Directions

Mamdouh Skafi, Santino Caserta, Ernesto Vigna, Antonella Bruzzese, Nicola Amodio, Eugenio Lucia, Virginia Olivito, Caterina Labanca, Francesco Mendicino iD, Maria Eugenia Alvaro, Fortunato Morabito, Enrica Antonia Martino und 1 weitere

European Journal of Haematology · 2026

DOI: 10.1111/ejh.70129 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift European Journal of Haematology, 2026. Verfasst von Mamdouh Skafi und 12 weiteren Autor:innen. Beteiligte Einrichtung: Emergency and Internal Medicine Department, Saint Joseph Hospital, East Jerusalem, Palestine. Hauptthemen laut MEDLINE: Lymphoma, Large B-Cell, Diffuse. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Diffuse large B‐cell lymphoma (DLBCL) remains the most common aggressive lymphoma, representing a biologically heterogeneous disease with diverse clinical behaviors. For more than two decades, R‐CHOP has been the cornerstone of frontline treatment, curing approximately two‐thirds of patients. Despite this success, a substantial subset—particularly those with high‐risk biology, double‐hit genetics, activated B‐cell‐like (ABC) subtype, or adverse clinical features—still experience relapse or refractory disease. Recent advances in lymphoma biology, immunotherapy, and targeted therapy have stimulated intense interest in improving frontline outcomes. Strategies include optimizing cytotoxic backbone regimens, incorporating antibody–drug conjugates (ADCs), immunomodulatory agents (IMiDs), bispecific antibodies, and exploring the feasibility of frontline CAR‐T cell therapy. This review provides a comprehensive and discursive synthesis of the biological rationale, clinical evidence, trial results, and practical considerations shaping contemporary frontline treatment. We highlight the emerging role of molecular subtyping, the tumor microenvironment, and high‐risk biomarkers, while discussing ongoing challenges and opportunities in integrating novel modalities into standard practice. Although R‐CHOP remains the universal backbone, the therapeutic landscape is entering a transformative era, with polatuzumab‐based regimens, bispecific combinations, and precision‐guided approaches positioned to redefine frontline care for selected subgroups.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lymphoma, Large B-Cell, DiffuseHumansAntineoplastic Combined Chemotherapy ProtocolsTumor MicroenvironmentTreatment OutcomeBiomarkers, TumorDisease ManagementCombined Modality TherapyImmunotherapyMolecular Targeted TherapyImmunoconjugates

Substanzen

Biomarkers, TumorImmunoconjugates

Autor:innen und Institutionen

  • Emergency and Internal Medicine Department, Saint Joseph Hospital, East Jerusalem, Palestine.
  • Hematology Unit, Department of Onco-Hematology, AO of Cosenza, Cosenza, Italy.
  • Department of Experimental and Clinical Medicine, University of Catanzaro, Catanzaro, Italy.
  • AIL Sezione di Cosenza, Cosenza, Italy.
  • Department of Pharmacy, Health and Nutritional Science, University of Calabria, Rende, Italy.

ORCID-Profile: Francesco Mendicino, Massimo Gentile

Zitieren

APA

Skafi, M., Caserta, S., Vigna, E., Bruzzese, A., Amodio, N., Lucia, E., Olivito, V., Labanca, C., Mendicino, F., Alvaro, M. E., Morabito, F., Martino, E. A., & Gentile, M. (2026). Frontline Therapy in Diffuse Large B‐Cell Lymphoma: Evolving Standards, Biological Insights, and Future Directions. European Journal of Haematology. https://doi.org/10.1111/ejh.70129

Vancouver

Skafi M, Caserta S, Vigna E, Bruzzese A, Amodio N, Lucia E, et al. Frontline Therapy in Diffuse Large B‐Cell Lymphoma: Evolving Standards, Biological Insights, and Future Directions. European Journal of Haematology. 2026. doi:10.1111/ejh.70129

BibTeX
@article{Skafi2026,
  author = {Skafi, Mamdouh and Caserta, Santino and Vigna, Ernesto and Bruzzese, Antonella and Amodio, Nicola and Lucia, Eugenio and Olivito, Virginia and Labanca, Caterina and Mendicino, Francesco and Alvaro, Maria Eugenia and Morabito, Fortunato and Martino, Enrica Antonia and Gentile, Massimo},
  title = {Frontline Therapy in Diffuse Large B‐Cell Lymphoma: Evolving Standards, Biological Insights, and Future Directions},
  journal = {European Journal of Haematology},
  year = {2026},
  doi = {10.1111/ejh.70129}
}
Kostenlos starten →